From what 5 stock analysts predict, the share price for Pacific Biosciences of California Inc (PACB) might increase by 84.67% in the next year. This is based on a 12-month average estimation for PACB. Price targets go from $8.00 to $14.00. The majority of stock analysts believe PACB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedPACB 3 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Pacific Biosciences of California Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PACB. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
david westenberg Piper Sandler | Hold | $8.0 | rated | Feb 16, 2024 |
john sourbeer UBS | Buy | $12.0 | maintained | Feb 16, 2024 |
kyle mikson cfa Canaccord Genuity | Buy | $14.0 | maintained | Feb 16, 2024 |
ross osborn Cantor Fitzgerald | Buy | $9.0 | maintained | Feb 16, 2024 |
luke sergott Barclays | Hold | $8.0 | maintained | Jan 25, 2024 |
mason carrico Stephens | Buy | $11.0 | rated | Dec 13, 2023 |
doug schenkel Wolfe Research | Hold | None | initiatedcoverage | Dec 12, 2023 |
daniel brennan TD Cowen | Buy | $19.0 | maintained | Nov 6, 2023 |
sung ji nam Scotiabank | Buy | $15.0 | reiterated | Nov 1, 2023 |
tejas savant Morgan Stanley | Hold | $10.0 | maintained | Oct 24, 2023 |
matthew sykes Goldman Sachs | Buy | $11.0 | maintained | Oct 17, 2023 |
eve burstein Bernstein | Buy | $11.0 | initiatedcoverage | Sep 28, 2023 |
rachel vatnsdal J.P. Morgan | Buy | $16.0 | maintained | Aug 3, 2023 |
jack meehan Nephron | Buy | $16.0 | initiatedcoverage | May 16, 2023 |
julia qin J.P. Morgan | Buy | $13.0 | maintained | Nov 17, 2022 |
gary tenner D.A. Davidson | Hold | $25.0 | maintained | Oct 24, 2022 |
tycho peterson J.P. Morgan | Buy | $30.0 | maintained | Feb 16, 2022 |
steven mah Cowen & Co. | Buy | $52.0 | upgraded | Feb 11, 2021 |
craig bijou Bank of America Securities | Buy | $5.0 | initiatedcoverage | Mar 9, 2020 |
jordan abrams Cantor Fitzgerald | Hold | $8.0 | maintained | Jun 20, 2019 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
When did it IPO
2010
Staff Count
769
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Christian O. Henry M.B.A.
Market Cap
$1.54B
In 2023, PACB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PACB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
EXTR-USD
$11.83
NTCT-USD
$22.26
$70.91
MXL-USD
$19.57
$20.09
PTON-USD
$4.54